💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Lopinavir

CHEMBL729 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
628.8 g/mol
LogP
5.9
Phase
4

An HIV protease inhibitor used exclusively in combination with ritonavir (as Kaletra) to boost its blood levels and treat HIV infection. The lopinavir-ritonavir combination is a cornerstone of antiretroviral therapy for both adults and children.

आणविक भार

628.8000 g/mol

LogP

5.90

TPSA

120.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

चिकित्सीय क्षेत्र

HIV/एड्स अनिद्रा अस्थमा इम्यूनोलॉजी उच्च रक्तचाप क्षय रोग (ट्यूबरकुलोसिस) जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर टाइप 2 मधुमेह दर्द प्रबंधन दीर्घकालिक दर्द मलेरिया लिम्फोमा संक्रामक रोग हाइपरलिपिडेमिया हृदय विफलता हृदय-संवहनी रोग हेपेटाइटिस C

क्रिया का तंत्र

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C37H48N4O5

                    

                    
                    

                        
HBD / HBA

                        
4 / 5

                    

                    
                    

                        
घूर्णनीय बंधन

                        
15

                    

                    
                    
                    

                        
भारी परमाणु

                        
46

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
An HIV protease inhibitor used exclusively in combination with ritonavir (as Kaletra) to boost its blood levels and treat HIV infection. The lopinavir-ritonavir combination is a cornerstone of antiretroviral therapy for both adults and children.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Lopinavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL729.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 92727.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.